Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease

dc.contributor.authorRoberts, K.
dc.contributor.authorPei, D.
dc.contributor.authorCampana, D.
dc.contributor.authorPayne-Turner, D.
dc.contributor.authorLi, Y.
dc.contributor.authorCheng, C.
dc.contributor.authorSandlund, J.
dc.contributor.authorJeha, S.
dc.contributor.authorEaston, J.
dc.contributor.authorBecksfort, J.
dc.contributor.authorZhang, J.
dc.contributor.authorCoustan-Smith, E.
dc.contributor.authorRaimondi, S.
dc.contributor.authorLeung, W.
dc.contributor.authorRelling, M.
dc.contributor.authorEvans, W.
dc.contributor.authorDowning, J.
dc.contributor.authorMullighan, C.
dc.contributor.authorPui, C.
dc.date.issued2014
dc.description.abstractAbstract not available
dc.description.statementofresponsibilityKathryn G. Roberts, Deqing Pei, Dario Campana, Debbie Payne-Turner, Yongjin Li, Cheng Cheng, John T. Sandlund, Sima Jeha, John Easton, Jared Becksfort, Jinghui Zhang, Elaine Coustan-Smith, Susana C. Raimondi, Wing H. Leung, Mary V. Relling, William E. Evans, James R. Downing, Charles G. Mullighan, and Ching-Hon Pui
dc.identifier.citationJournal of Clinical Oncology, 2014; 32(27):3012-3020
dc.identifier.doi10.1200/JCO.2014.55.4105
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.orcidMullighan, C. [0000-0002-1871-1850]
dc.identifier.urihttp://hdl.handle.net/2440/103707
dc.language.isoen
dc.publisherAmerican Society of Clinical Oncology
dc.relation.grantNHMRC
dc.rights© 2014 by American Society of Clinical Oncology
dc.source.urihttps://doi.org/10.1200/jco.2014.55.4105
dc.subjectGene expression profiling; Kaplan-Meier estimate; molecular targeted therapy; percusor cell lymphoblastic leukemia-lymphoma
dc.titleOutcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease
dc.typeJournal article
pubs.publication-statusPublished

Files